B · Normal
[Hengrui Medicine: Subsidiary receives clinical trial approval notice for HRS-2189 tablets] On October 28, Hengrui Medicine (600276.SH) announced that the company's subsidiary Shandong Shengdi Medicine has received the approval and issuance of a "Drug Clinical Trial Approval Notice" for HRS-2189 tablets from the State Food and Drug Administration and will launch clinical trials in the near future. This drug is a new KAT6 inhibitor, intended to be used to treat advanced malignant tumors. Currently, no drug with the same target has been approved for marketing at home and abroad. The cumulative investment in research and development of related projects is approximately 55.3 million yuan.
A-share announcement express 🕐 2026-10-28 17:41
#clinical trial #A-share announcement express
Save as Image Generate a beautiful long image to share on Moments or in group chats Generate now ⬇
← Back to Telegraph

Related telegraphs

[Pengding Holdings: Q3 net profit increased by 41% month-on-month] On October 28 10-28 18:34 [Sanhua Intelligent Control: Net profit in the first three quarters fell 5.40% y 10-28 18:33 [China Satellite: Net profit in the first three quarters increased by 473.40% ye 10-28 18:28 [Zhang Jianping has become the fourth largest shareholder of Feilong Shares] On 10-28 18:28 [Yibo Technology: Net profit in the first three quarters increased by 834.98% ye 10-28 18:27 [Yibo Technology: Subsidiary plans to sign a 1 billion yuan AI computing power h 10-28 18:25

Comments

0/500
Captcha (click to refresh)
No comments yet